Drug Profile
Research programme: antibacterials - FAB Pharma
Alternative Names: MUT 11931; MUT-37307Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Mutabilis
- Developer FAB Pharma; Mutabilis
- Class Phenols; Small molecules
- Mechanism of Action Enoyl-ACP reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in France (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in France (Parenteral)
- 31 Oct 2011 Preclinical development is ongoing in France